Cardiff Oncology(US:CRDF) ZACKSยท2024-11-08 00:10Group 1 - Cardiff Oncology reported a quarterly loss of $0.25 per share, better than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of 7.41% [1] - The company posted revenues of $0.17 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 32%, compared to revenues of $0.14 million a year ago [2] - Cardiff Oncology shares have increased approximately 157.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 24.3% [3] Group 2 - The earnings outlook for Cardiff Oncology is mixed, with the current consensus EPS estimate for the coming quarter at -$0.27 on revenues of $0.14 million, and -$1.01 on revenues of $0.55 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Cardiff Oncology belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] Group 3 - Cardiff Oncology has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times in the same period [2] - The estimate revisions trend for Cardiff Oncology is currently mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6]